Agenda

Wednesday, March 1, 2023

09:15 am - 09:30 am EST Main auditorium
Welcome

Liora Schultz and Nirali Shah

09:30 am - 09:45 am EST Main auditorium
Introductory Keynote

Reflections of emergent challenges over a decade of CAR T cell therapy

Stephan Grupp (CHOP)

09:45 am - 10:00 am EST Main auditorium
Patient Perspective

Patrick McSweeney, RN

10:00 am - 11:00 am EST Main auditorium
Session 1: Current best practices using CAR T-cells in pediatric B-ALL

Session Chairs: Kevin Curran (MSKCC) and Ted Laetsh (CHOP)

 

Clinical variables impacting CAR outcomes , Liora Schultz (Stanford)

 

Impact of prior therapy and CAR timing, Regina Myers (CHOP)

 

CIDR and CAR-specific data capture, Marcelo Pasquini (CIBMTR)

 

Global CAR experience and insights gained, Elad Jacoby (Sheeba)

 

Discussion

 

11:00 am - 11:15 am EST
Break
11:15 am - 12:45 pm EST Main auditorium
Session 2: Relapse prevention and management following CAR T-cells

Session Chairs: Persis Amrolia (GOSH) and Amy Moskop (MCW)

 

Relapse Prevention

 

Post-CAR monitoring with NGS/BCMA, Michael Pulsipher (Utah)

 

Humanized CAR, Shannon Maude (CHOP)

 

Post-CAR HSCT and CAR-CURE Trial, Corinne Summers (SCH)

 

CD19 APCs for relapse prevention, Colleen Annesley (SCH)

 

Relapse management

 

CAR reinfusions, Andre Baruchel (Universite Hopital Robert Debre)

 

Relapse phenotype and implications, Adam Lamble (SCH)

 

Combinatorial CAR and CD22 CAR T-cells (CAR), Nirali Shah (NCI)

 

Discussion

 

12:45 pm - 01:15 pm EST Lobby
Lunch/Group Photo

*PLEASE GO TO LOBBY FOR PHOTO

01:15 pm - 01:35 pm EST E1/E2
Lunch Symposium

Keynote: Accelerating pediatric CAR T-cell progress: Point of Care Manufacturing and Expanding Access

 

Claudia Rossig (University of Munster)

01:35 pm - 01:45 pm EST
Break
01:45 pm - 03:00 pm EST Main auditorium
Session 3: CAR T-cell associated emergent toxicities: prevention and management

Session Chairs: Emily Hsieh (CHLA) and Jenna Rosoff (Lurie)

 

Pre-emptive/prophylaxis for CRS, Rebecca Gardner (Seattle Children’s)

 

ICANS (pre-emptive and IT), Haneen Shalabi (NCI)

 

HLH-like toxicities, Kevin McNerney (JHH All Childrens)

 

Vaccination and Immune Reconstitution, Joshua Hill (Fred Hutch, Virtual)

 

Delayed Toxicities, Rebecca Epperly (St. Jude)

 

Discussion

 

03:00 pm - 03:15 pm EST
Break
03:15 pm - 04:15 pm EST
Session 4: Concurrent Sessions
Main auditorium
Session 4A: Special considerations for CAR T-cells in unique populations

Session 4A: Special considerations for CAR T-cells in unique populations

Chairs: Lena Winestone (UCSF) and Sue Rheingold (CHOP)

 

Special populations: Infants; DS, Sara Ghorashian (GOSH)

 

Cytogenetics, Allie Leahy (CHOP)

 

Access, Karen Chao (MCW)

 

Driving CARs forward, Deepa Bhojwani (CHLA)

 

Patient Reported Outcomes, Angela Steineck (MCW)

 

Special populations: AYA, Lori Muffly (Stanford, Virtual)

E1/E2
Session 4B: CAR T-cell biologic correlatives guiding future research 

Session 4B: CAR T-cell biologic correlatives guiding future research 

Chairs: Christian Capitini (Wisc) and John Ligon (UFl)

 

Neurocognitive testing, Pam Wolters (NCI)

 

CAR T-cell Correlatives, Sneha Ramakrishna (Stanford)

 

Manufacturing changes, Francesco Ceppi (University Hospital of Lausanne)

 

Fludarabine PKs, Frisco Calkoen (Princess Maxima Center)

 

Blina/Ino Sequential immunotherapy, Lia Gore (Colorado)

 

Discussion 

04:15 pm - 04:30 pm EST
Break
04:30 pm - 05:20 pm EST Main auditorium
Session 5: Beyond B-cell ALL

Chairs: Aimee Talleur (St. Jude) and Vanessa Fabrizio (Colorado)

 

T-cell ALL, Rayne Rouce (TCH)

 

AML, Richard Aplenc (CHOP)

 

CNS Tumors, Robbie Majzner (Stanford)

 

Solid Tumors, Rosa Nguyen (NCI)

 

Discussion

05:20 pm - 05:45 pm EST Main auditorium
Final Keynotes

CAR Scalability: Addressing issues of next-gen manufacturing and engineering

 

Crystal Mackall (Stanford)

05:45 pm - 05:55 pm EST
Patient Perspective

Lisa Ward

05:55 pm - 06:00 pm EST
Conclusion and Future Directions

Liora Schultz and Nirali Shah